Abstract
Marie-Christine Bene
Initiated by Gerrit Jan Schuurhuis, a group of European LeukmiaNet members met to share experience on minimal/measurable residual disease (MRD) in acute myeloblastic leukemia. This gave rise to a seminal paper in 2018 with more recent revisions. This group has dealt with MRD in flow cytometry as well as with molecular tools as well as with clinical applications.
